Page header

Recommendation of the President – Xuriden (uridine triacetate)

On 8 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 4/2026 on the validity of granting approval for the reimbursement of the medicinal product Xuriden (uridine triacetate) for the indication of uridine monophosphate synthase deficiency

Publication in Public Information Bulletin (BIP) >>